CClinicalTrials.gg
TerminatedNCT04667559Updated Oct 25, 2023

A Study to Evaluate the Conformis iTotal Identity Knee Replacement System

An observational study in Osteoarthritis, Knee, sponsored by Restor3D. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Restor3D · Observational

Why this study was terminated
Decision of investigational team
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective multicenter study located in the United States. Subjects will be implanted with an iTotal Identity Knee Replacement System and followed for 10 years post implantation.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis, Knee

3,303 studies on the registry are indexed under Osteoarthritis, Knee; 608 are open to participants now.

This study's enrollment of 22 is below the median of 100 across 473 observational studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Restor3D is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with clinical condition indicated in the approved Instructions for Use for the Conformis iTotal Identity Knee Replacement System

Inclusion criteria

  • Clinical condition included in the approved Indications For Use for the iTotal Identity CR KRS
  • Osteoarthritis, as confirmed by the investigator's assessment of disease status at screening visit that warrants a TKR procedure. Disease status is assessed by Clinical and Radiographic assessment.
  • Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits
  • > 18 years of age with complete development of musculoskeletal structures

Exclusion criteria

Exclusion Criteria:

  • Simultaneous bilateral procedure required
  • BMI > 40
  • Active malignancy (defined as a history of any invasive malignancy - except nonmelanoma skin cancer), unless subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years
  • Poorly controlled diabetes (defined as HbA1c >7 or Investigator discretion)
  • Neuromuscular conditions which prevent subject from participating in study activities
  • Active local or systemic infection which precludes TKR procedure
  • Immunocompromised in the opinion of the Investigator
  • Medically diagnosed fibromyalgia or similar conditions that might impact the subject's ability to differentiate source of pain
  • Rheumatoid arthritis or other forms of inflammatory joint disease
  • Loss of bone or musculature, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated on, to an extent that the procedure is unjustified
  • Diagnosed with or receiving treatment for osteoporosis that is likely to confound results in the opinion of the Investigator
  • Other physical disability affecting the hips, spine, or contralateral knee that is likely to confound results in the opinion of the Investigator
  • Severe instability due to advanced loss of osteochondral structure
  • Prior arthroplasty of the affected knee, including High Tibial Osteotomy (HTO)
  • Compromised PCL or collateral ligament
  • Severe fixed valgus or varus deformity of >15º
  • Extensor lag > 15º
  • Fixed flexion contracture ≥ 15º
  • Unwilling or unable to comply with study requirements
  • Participation in another clinical study which would confound results
  • Allergy to any of the implant materials
  • Pregnant or planning to become pregnant prior to study TKR procedure (in case of pregnancy after study TKR procedure, eligibility to continue with the protocol will be reviewed)
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No

Interventions

  • DeviceConformis iTotal Identity Knee Replacement System

    The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.

06

What researchers measure

Primary outcomes

  1. Pain and function

    Measured by 2011 Knee Society Clinical Rating Score (objective knee score 0-125, function score 0-100, satisfaction score 0-40, expectation score 0-15 with higher scores meaning better outcome)

    Time frame: 2 years post implantation

Secondary outcomes

  1. Revision rate

    Time frame: Post implantation up to 10 years

  2. Incidence of major procedure-related and device-related complications, including infection rate

    Time frame: Post implantation up to 10 years

  3. Post-operative hip-knee-ankle limb alignment (with 180 degrees being the expected outcome, plus or minus 5 degrees), if long leg x-rays available

    Time frame: Post implantation up to 10 years

  4. Number of patients demonstrating radiographic loosening, radiolucency

    Review of x-rays to subjectively determine evidence of implant disassociation with bone

    Time frame: Post implantation up to 10 years

  5. Length of procedure

    Time frame: Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)

  6. Length of hospital stay in hours

    Time frame: Time from patient admission to hospital before surgery til discharge from hospital (up to 72 hours)

  7. blood loss during surgery

    Time frame: Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)

  8. blood transfusion rates

    Time frame: Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)

07

Study locations

2 sites
  • Personalized Orthopedic Research Institute
    Boynton Beach, Florida 33437, United States
  • Tennessee Orthopaedic Alliance
    Nashville, Tennessee 37203, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04667559
Lead sponsor
Restor3D
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Oct 12, 2020
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Last update
Oct 25, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion